for the hypertension has been detected. It is also worthwhile to ensure that the patient understands his or her drug regime and is actually taking any treatment as prescribed. The next consideration is whether the choice of first-line drug was logical in the first place.
There is reasonable evidence that drugs which work, wholly or in part, by blocking the reninangiotensin system, tend to be somewhat less effective in patients whose circulating renin and angiotensin levels are low. [4] [5] [6] These drugs are the betareceptor blockers, the angiotensin-converting enzyme (ACE) inhibitors and the angiotensin receptor antagonists. 'Low renin' states are found in the elderly, black/Afro-Caribbean patients and patients with non-insulin-dependent diabetes mellitus (NIDDM). [7] [8] [9] [10] The more rational first-line agents for such patients are the thiazide diuretics or the calcium channel blockers (CCBs). However, there is now evidence that the ACE inhibitors (and possibly the angiotensin II receptor blockers) are specifically indicated in patients with diabetes mellitus because of their beneficial effects on nephropathy, retinopathy, left ventricular hypertrophy and the possible prevention of macro-vacsular end-organ damage. [11] [12] [13] [14] These beneficial effects may be independent of the anti-hypertensive properties and indeed blood pressure may be relatively uncontrolled. What then are the best add-in drugs?
There are logical add-on therapies and less logical combinations. For example beta-blockers work well Correspondence: Professor DG Beevers with the dihydropyridine CCBs and by offsetting tachycardia and sympathetic stimulation they may actually reduce side effects. 15 There is good evidence of synergy between the thiazide diuretics and the beta-blockers, the ACE inhibitors 16 as well as the angiotensin receptor antagonists. 17 Similarly, the CCBs work well in combination with the classes of drugs which block the generation or effects of angiotensin II. 18, 19 By contrast there are some drug combinations which are not particularly effective and some are unsafe. There is little synergy between thiazide diuretics and the dihydropyridine CCBs. 20, 21 The addition of an ACE inhibitor to a beta-blocker also tends to be less effective because the beta-blockers will already have blocked renin release. 22, 23 In order to aid the clinician in sensible prescribing we have developed the 'Birmingham Hypertension Square' for add-in drugs in the management of hypertension (Figure 1 ). Clearly such a simplified system cannot cover all eventualities. The clinician should opt, however, to approach the square from any corner, with first-line drugs chosen logically. The optimal second-line agents are immediately adjacent and indicated by the arrows. There are several exceptions to the guidelines suggested by the square. For example it provides guidance only for the use of the dihydropyridine CCBs. It is generally held that the phenylalkylamine CCB, verapamil, can be hazardous when used in combination with a betablocker because of negative ionotropism and chronotropism. It has, however, been reported, that there is some synergy between verapamil and the dihydropyridine CCB, nitrendipine. 24 The role of the alpha receptor blockers (eg, doxazosin) and the centrally acting agents (eg, moxonidine, rilmenidine and methyldopa) in combination therapies is less certain and side effects may limit their use. There is some evidence that the alpha-blockers are synergistic with beta-blockers and the ACE inhibitors although the side effect of stress incontinence limits the use of alpha-blockers in women. 25 We therefore do not routinely recommend the use of these drugs as the first choice of 'add-in' drugs at the present state of knowledge.
The choice of third-line agents for use with the Birmingham Hypertension Square is more the subject of speculation, anecdote and little reliable trial evidence. At this stage, in resistant hypertension, where the outlook is more closely related to the achieved blood pressure on therapy rather than the initial severity of the hypertension, 26, 27 the Birmingham Hypertension Square may provide some guidance.
The choice of rational first and second-drugs using our system, could lead to some financial savings for health care resources. For example, in an elderly Afro-Caribbean patient, the use of enalapril with atenolol added in could cost UK £19.91 per month and will be relatively ineffective. 28 The substitution of bendrofluazide alone at UK £0.15 per month may well be more effective, and more acceptable. If a thiazide diuretic drug cannot be used then a CCB used alone is a reasonable alternative.
